Hepatitis C virus genetic variability in patients undergoing antiviral therapy

Virus Research

Volumn 127, Issue 2, 2007, Pages 185-194

  Cristina, Juan ^a   Moreno, María del Pilar ^a   Moratorio, Gonzalo ^a  

^a Facultad de Ciencias   (Uruguay)

Author keywords

Antiviral therapy; Evolution; Hepatitis C virus; Quasispecies

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; GLYCOPROTEIN; NONSTRUCTURAL PROTEIN 5A; RIBAVIRIN;

ARTICLE; DISEASE TRANSMISSION; DRUG POTENTIATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PERINATAL INFECTION; PRIORITY JOURNAL; RNA REPLICATION; T LYMPHOCYTE; TREATMENT RESPONSE; UNINDEXED SEQUENCE;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; MUTATION; VARIATION (GENETICS); VIRUS REPLICATION;

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 34447333097     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2007.02.023     Document Type: Article

References (111)

1. Airaksinen A., Pariente N., Menendez-Arias L., and Domingo E. Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311 (2003) 339-349
2. Alter H.J., and Seeff L.B. Semin. Liver Dis. 20 (2000) 17-35
3. Baccam P., Thompson R., Fedrigo O., Carpenter S., and Cornette J.L. PAQ: partition analysis of quasispecies. Bioinformatics 17 (2001) 16-22
4. Bartosch B., Vitelli A., Granier, et al. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278 (2003) 41624-41630
5. Biebricher C.K., and Eigen M. The error threshold. Virus Res. 107 (2005) 117-127
6. Chambers T.J., Fan X., Droll D.A., Hembrador E., Slater T., Nickells M.W., Dustin L.B., and Dibisceglie A.M. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J. Virol. 79 (2005) 3071-3083
7. Cheng G., Zhong J., and Chisari F.V. Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 8499-8504
8. Cody S.H., Nainan O.V., Garfein R.S., et al. Hepatitis C virus transmission from an anesthesiologist to a patient. Arch. Intern. Med. 162 (2002) 345-350
9. Contreras A.M., Hisasa Y., He W., Terella A., Schmidt E.V., and Chung R.T. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J. Virol. 76 (2002) 8505-8517
10. Crotty S., Cameron C.E., and Andino R. Ribavirin's antiviral mechanisms of action: lethal mutagenesis?. J. Mol. Med. 80 (2002) 86-95
11. Crotty S., Cameron C.E., and Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 6895-6900
12. Davidson F., Simmonds P., Ferguson J.C., Jarvis L.M., Dow B.C., Follett E.A.C., Seed C.R.G., Krusius T., Lin C., Medgyesu G.A., Kiyokawa H., Olim G., Duraisamy G., Cuypers T., Seed A.A., Ten D., Conradie J., Kew M.C., Lin M., Nuchaprayoon C., Ndimbe O.K., and Yap P.L. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding regions. J. Gen. Virol. 76 (1995) 1197-1204
13. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N. Engl. J. Med. 339 (1998) 1493-1499
14. Domingo E. Antiviral strategy on the horizon. Virus Res. 107 (2005) 115-116
15. Domingo E., Biebricher C., Eigen M., and Holland J.J. Quasispecies and RNA virus evolution: principles and consequences (2001), Landes Biosci., Austin
16. Domingo E., Baranowski E., Ruiz-Jarabo C.M., Martín-Hernandez A.M., Saiz J.C., and Escaramis C. Quasispecies structure and persistence of RNA viruses. Emerg. Infect. Dis. 4 (1998) 521-527
17. Duverlie G., Khorsi H., Castelain S., Jaillon O., Izopet J., Lunel F., Eb F., Penin F., and Wychowski C. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J. Gen. Virol. 79 (1998) 1373-1381
18. Enomoto N., Sakuma I., Asahina Y., Kurosaki M., Murakami T., Yamamoto C., Izumi N., Marumo F., and Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitution in the NS5A region. J. Clin. Invest. 96 (1995) 224-230
19. Enomoto N., Sakuma I., Asahina Y., et al. Mutations in the nonstructural protein 5A and response to interferon in patients with chronic hepatitis C virus 1b intection. N. Engl. J. Med. 334 (1996) 77-81
20. European Paediatric Hepatitis C Virus Network, 2005. Clin. Infect. Dis. 41, 45-51.
21. Fang S.H., Hwang L.H., Chen D.S., and Chiang B.L. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J. Hepatol. 33 (2000) 791-798
22. Farci P., Quinti I., Farci S., Alter H.J., Strazzera R., Palomba E., Coiana A., Cao D., Casadel A.M., Ledda R., Iorio R., Vegnente A., and Diaz G. Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 8475-8480
23. Farci P., Strazerra R., Alter H.J., Farci S., Degloannis D., Colana A., Peddis F., Usai F., Serra G., Chessa L., Diaz G., Balestrieri A., and Purcell R.H. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 3081-3086
24. Farci P., Shimoda A., Coiana, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 (2000) 339-344
25. Feliu A., Gay E., Garcia-Retortillo M., Saiz J.C., and Foms X. Evolution of hepatitis C virus quasispecies immediately following liver transplantation. Liver Transpl. 10 (2004) 1131-1139
26. Felsenstein J. PHYLIP: phylogeny inference package, version 3.572c (1993), University of Whashington, Seattle, WA
27. Fint S.J., Enquist L.W., Racaniello V.R., and Skalka A.M. Principles of virology: molecular biology, pathogenesis, and control of animal viruses (2004), ASM Press, Washington, DC
28. Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B.B., Pezzanera M., Tafi R., Arcuri M., Fattori E., Lahm A., Luzzago A., Vitelli A., Colloca S., Cortese R., and Nicosia A. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12 (2006) 190-197
29. Fried M.W., and Hadziyannis S.J. Treatment of chronic hepatitis C infection with peginterferons plus ribavirin. Semin. Liver Dis. 24 (2004) 47-54
30. Gaudy C., Lambele M., Moreau A., Veillon P., Lunel F., and Goudeau A. Mutations within the Hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome. J. Clin. Microbiol. 43 (2005) 750-754
31. Gale M., Jorth M.J., Tang N.M., Tan S.L., Hopkins D.A., Dever T.E., Polyak S.J., Gretch D.R., and Katze M.G. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230 (1997) 217-227
32. Gerotto M., Resti M., Dal Pero F., Migliorato I., Alberti A., and Bortolotti F. Evolution of hepatitis C virus quasispecies in children with chronic hepatitis C. Infection 34 (2006) 62-65
33. Gimenez-Barcons M., Franco S., Suarez Y., et al. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrosis. Hepatology 34 (2001) 158-167
34. Goffard A., and Dubuisson J. Glycosylation of hepatitis C virus envelope proteins. Biochimie 85 (2003) 295-301
35. Gong G., Waris G., Tanveer R., and Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kB. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 9599-9604
36. Gretch D.R., Polyak S.J., Wilson J.J., Carithers Jr. R.L., Perkins J.D., and Corey L. Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J. Virol. 70 (1996) 7622-7631
37. Guglietta S., Garbuglia A.R., Pacciani V., Scotta C., Perrone M.P., Laurenti L., Spada E., Mele A., Capobianchi M.R., Taliani G., Folgori A., Vitelli A., Ruggeri L., Nicosia A., Piccolella E., and Del Porto P. Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection. Euro. J. Immunol. 35 9 (2005) 2627-2637
38. Gupta R., Subramani M., Khaja M.N., Madhavi C., Roy S., Habibullah C.M., and Das S. Analysis of mutations within the 5′ untranslated region, interferon sensitivity region, and PePHD region as a function of response to interferon therapy in Hepatitis C virus-infected patients in India. J. Clin. Microbiol. 44 (2006) 709-715
39. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., Murthy K.K., Rice C.M., and Walker C.M. HCV persistence and immune evasion in the absence of memory T cell help. Science 302 (2003) 659-662
40. Hijikata M., Mizuno K., Rikihisa T., Shimizu Y.K., Iwamoto A., Nakajima N., and Yoshikura H. Selective transmission of hepatitis C virus in vivo and in vitro. Arch. Virol. 140 (1995) 1623-1628
41. Hong Z., and Cameron C.E. Pleiotropic mechanisms of ribavirin antiviral activities. Prog. Drug. Res. 59 (2002) 41-69
42. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 36 (2002) S21-S29
43. Hu K.Q., Vierling J.M., and Redeker A.G. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J. Viral. Hepat. 8 (2001) 1-18
44. Inchauspe G., Zebedee S., Lee D.H., Sugitani M., Nasoff M., and Prince A.M. Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 10292-10296
45. Kantzanou M., Lucas M., Barnes E., Komatsu H., Dusheiko G., Ward S., Harcourt G., and Klenerman P. Viral escape and T cell exhaustion in hepatitis C virus infection analysed using class I peptide tetramers. Immunol. Lett. 85 (2003) 165-171
46. Kojima M., Osuga T., Tsuda F., Tanaka T., and Okamoto H. Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitiss C virus in chimpanzees. Virology 204 (1994) 665-672
47. Kuiken C., Yusim K., Boykin L., and Richardon R. The HCV sequence database. Bioinformatics 21 (2005) 379-384
48. Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P., Bos M., Cameron D.R., Cartier M., and Cordingley M.G. Nature 426 (2003) 186-189
49. Laskus T., Wilkinson J., Gallegos-Orozco J.F., Radkowski M., Adair D.M., Nowicki M., Operskalsi E., Buskell Z., Seeff L.B., Vargas H., and Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 127 (2004) 764-776
50. Lechner F., Gruener N.H., Urbani S., Uggeri J., Santantonio T., Kammer A.R., Cerny A., Phillips R., Ferrari C., Pape G.R., and Klenerman P. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur. J. Immunol. 30 (2000) 2479-2487
51. Lee H., Shin H., Wimmer E., and Paul A.V. cis-acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome. J. Virol. 78 20 (2004) 10865-10877
52. Leyseen P., Balzarini J., De Clercq E., and Neyts J. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79 3 (2005) 1943-1947
53. Lin H.J., Seeff L.B., Barbosa L., and Hollinger F.B. Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time. Hepatology 34 (2001) 424-429
54. β promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 6001-6006
55. Maag D., Castro C., Hong Z., and Cameron C.E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 276 (2001) 46094-46098
56. MacDonald A., and Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J. Gen. Virol. 85 (2004) 1502-2485
57. Majumder M., Ghosh A.K., Steele R., Ray R., and Ray R.B. Hepatitis C virus NS5A physically associates with p53 and regulates p21/wafl gene expression in a p53-dependent manner. J. Virol. 75 (2001) 1401-1407
58. Manzin A., Solforosi L., Debiaggi M., Zara F., Tanzi E., Romano L., Zanetti A.R., and Clementi M. Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J. Virol. 74 (2000) 4327-4334
59. Martell M., Esteban J.L., Quer J., Genesca J., Weiner A., Esteban R., Guardia J., and Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66 (1992) 3225-3229
60. McHutchinson J.G., Gondon S.C., Schiff E.R., et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis. N. Engl. J. Med. 339 (1998) 1485-1492
61. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., and Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437 (2005) 1167-1172
62. Murphy M.D., Rosen H.R., Marousek G.I., and Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 regions as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig. Dis. Sci. 47 (2002) 1195-1205
63. Ni Z.J., and Wagman A.S. Progress and development of small molecule HCV antivirals. Cur. Opin. Drug. Discov. Devel. 7 (2004) 446-459
64. Nousbaum J., Polyak S.J., Ray S.C., Sullivan D.G., Larson A.M., Carithers R.L., and Gretch D.R. Prospective characterization of full-lenght hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J. Virol. 74 (2000) 9028-9038
65. Ohto, H., Terazawa, S., Sasaki, N., Hino, K., Ishiwata, C., Kako, M., Ujie, N., Endo, C., Matsui, A., et al., 1994. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N. Engl. J. Med. 330, 744-750.
66. Okamoto H., Kobata S., Tokita H., Inoue T., Woodfield G.D., Holland P.V., Al-Knawy B.A., Uzunalimoglu O., Miyakawa Y.U., and Mayumi M. A second-generation method of genotyping hepatitis C virus by the polymerase chain reaction with sense and antisense primers deduced from the core gene. J. Virol. Meth. 57 (1996) 31-45
67. Okamoto H., Sujiyama S., Okada K., Kurai K., Akahane Y., Sugai Y., Tanaka T., Sato K., Tsuda F., Miyakawa Y., and Mayumi M. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infection sources. J. Gen. Virol. 73 (1992) 673-679
68. Pariente N., Saleta S., and Airaksinen A. Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res. 107 (2005) 183-193
69. Pawlotsky J.M. Hepatitis C virus population dynamics during intection. Curr. Top. Microbiol. Immunol. 299 (2006) 261-284
70. Pawlotsky J.M. The nature of interferon-alfa resistance in hepatitis C virus infection. Curr. Opin. Infect. Dis. 16 (2003) 587-592
71. Pestova T.V., Shatsky I.N., Fletcher S.P., Jackson R.J., and Hellen C.U.T. A prokaryotic-like mode of cytoplasmic eukaryotic ribosome binging to the initiation codon during internal translation initiation of hepatitis C and classical swine fever virus RNAs. Genes. Dev. 12 (1998) 6783
72. Perales C., Martin V., Ruiz-Jarabo C.M., and Domingo E. Monitoring sequence space as a test for the target of selection in viruses. J. Mol. Biol. 345 (2004) 451-459
73. Polyak S.J., Khabar K.S.A., Paschal D.M., Ezelle H.J., Duverlie G., Barber G.N., Levy D.E., Mukaida N., and Gretch D.R. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75 (2001) 6095-6106
74. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., and Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352 (1998) 1426-1432
75. Puig-Basagoiti F., Forns X., Furcic I., Ampurdanes S., Gimenez-Barcons M., Franco S., Sanchez-Tapias J.M., and Saiz J.C. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C. J. Gen. Virol. 86 (2005) 1067-1075
76. Puig-Basagoiti F., Saiz J.C., Forns X., et al. Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C. J. Med. Virol. 65 (2001) 35-44
77. Ray S.C., Wang Y.M., Laeyendecker O., Ticehurst J.R., Villano S.A., and Thomas D.L. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J. Virol. 73 (1999) 2938-2946
78. Reyes G.R. The nonstructural NS5A protein of hepatitis C virus: an esxpanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J. Biomed. Sci. 9 (2002) 187-197
79. Robertson B., Myers G., Howard C., Brettin T., Bukh J., Gaschen B., Gojobori T., Maaertens G., Mizokami M., Nainan O., Netesov S., Nishioka K., Simmonds P., Smith D., Stuyver L., and Weiner A. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. Arch. Virol. 143 (1998) 2493-2503
80. Saiz J.C., Lopez-Labrador F.X., Ampurdanes S., Dopazo J., Foros X., Sanchez-Tapias J.M., and Rodes J. The prognostic relevante of the nonstructural 5A gene interferon sensitivity determining region is different in infections with genotype 1b and 3a isolates of hepatitis C virus. J. Infect. Dis. 177 (1998) 839-847
81. Schinkel J., Spoon W.J., and Kroes A.C. Meta-analysis of mutations in the NS5A gene and hepatitis C virus resistance to interferon therapy: uniting discordant conclusions. Antivir. Ther. 9 (2004) 275-286
82. Seifert U., Liermann H., Racanelli V., Halenius A., Wiese M., Wedemeyer H., Ruppert T., Rispeter K., Henklein P., Sijts A., Hengel H., Kloetzel P.M., and Rehermann B. Hepatitis C virus mutations affects proteasomal epitope processing. J. Clin. Invest. 114 (2004) 250-259
83. Severson W.E., Schmaljohn C.S., Javadian A., and Jonsson C.B. Ribavirin causes error catastrophe during Hantaan virus replication. J. Virol. 77 (2003) 481-488
84. Shiina M., and Rehermann B. Hepatitis C vaccines: inducing and challenging memory T cells. Hepatology 43 (2006) 1395-1398
85. Simmonds P., Bukh J., Combet C., Deleage G., Enomoto N., Feinstone S., Halfon P., Inchauspe G., Kuiken C., Maertens G., Mizokami M., Murphy D.G., Okamoto H., Pawlotsky J.M., Penin F., Sablon E., Shin I.T., Stuyver L.J., Thiel H.J., Viazov S., Weiner A.J., and Widell A. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hematology 42 (2005) 962-973
86. Simmonds P. Genetic diversity and evolution of hepatitis C virus 15 years on. J. Gen. Virol. 85 (2004) 3173-3188
87. Simmonds P., Holmes E.C., Cha T.A., Chan S.W., McOmish F., Irvine B., Beall E., Yap P.L., Kolberg J., and Urdea M.S. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74 (1993) 2391-2399
88. Soderholm J., Ahlen G., Kaul A., Frelin L., Alheim M., Barnfield C., Liljestrom P., Weiland O., Milich D.R., Bartenschlager R., and Sallberg M. Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 55 2 (2006) 266-274
89. Solmone, M., Girardi, E., Lalle, E., Abbate, I., D'Arminio-Monforte, A., Cozzi-Lepri, A., Alessandrini, A., Piscopo, R., Ebo, F., Cosco, L., Antonucci, G., Hipólito, G., Capobianchi, M.R., Hepal.Co.N.A. Study Group, I.Co.N.A. Study Group, 2006. Evolution of HVR-1 quasispecies alter 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy. Antivir. Ther. 11, 87-94.
90. Shoukry N., Grakoui A., Houghton M., Chien D.Y., Ghrayeb J., Reimann K.A., and Walker C.M. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197 (2003) 1645-1655
91. Shuhart M.C., Sullivan D.G., Bekele K., Harrington R.D., Kitahata M.M., Mathisen T.L., Thomassen L.V., Emerson S.S., and Gretch D.R. HIV infection and antiretroviral therapy: effect on hepatitis C quasispecies variability. J. Infect. Dis. 193 (2006) 1211-1218
92. Szabo G. Hepatitis C virus NS5A protein, a master regulator?. Gastroenterology 130 (2006) 995-998
93. Tam R.C., Lau J.Y., and Hong Z. Mechanisms of action of ribavirin in antiviral therapies. Antivir. Chem. Chemother. 12 (2001) 261-272
94. Tan Y.J., Lim S.G., and Hong W. Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfection. Curr. HIV Res. 4 (2006) 21-30
95. Tan S.L., He Y., Huang Y., and Gale Jr. M. Curr. Opin. Pharmacol. 4 (2004) 112-465
96. Tan S.L., and Katze M.G. How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284 (2001) 112
97. Tan S.L., Nakao H., He Y., Vijaysri S., Neddermann P., Jacobs B.L., Mayer B.J., and Katze M.G. NS5A, a non-structural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Scr homology 3 domain/ligand-dependent manner and perturbs mitogenic signalling. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5533-5538
98. Taylor D.R., Shi S.T., Romano P.R., Barber G.N., and Lai M.M. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 285 (1999) 107-110
99. Tovo P.A., Pembrey L.J., and Newell M.L. J. Infect. Dis. 181 (2000) 419-424
100. Thomson J.A., and Perni R.B. Hepatitis C NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Cur. Opin. Drug. Discov. Devel. 9 (2006) 606-617
101. Vignuzzi M., Stone J.K., and Andino R. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications. Virus Res. 107 (2005) 173-181
102. Vo N.V., Young K.C., and Lai M.M. Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 42 (2003) 10462-10471
103. Vogt M., Lang T., Frosner G., Klingler C., Sendl A.F., Wiebecke B., Langer B., Meisner H., and Hess J. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N. Engl. J. Med. 341 (1999) 866-870
104. Weiner A.J., Thaler M.M., Crawford K., Ching K., Kansopon J., Chien D.Y., Hall J.E., Hu F., and Houghton M. A unique predominant hepatitis C virus variant found in an infant born to a mother with multiple variants. J. Virol. 67 (1993) 4365-4368
105. Witherell G.W., and Beineke P. Statistical analysis of combined substitutions in non-structural 5A region of hepatitis C virus and interferon response. J. Med. Virol. 63 (2001) 8-16
106. Yoneyama M., Kikuchi M., Natsukawa T., Shinobu N., Imaizumi T., Miyagishi M., Taira K., Akira S., and Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5 (2004) 730-737
107. You S., Stump D.D., Branch A.D., and Rice C.M. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication. J. Virol. 78 (2004) 1352-1366
108. Young K.C., Lindsay K.L., Lee K.J., Liu W.C., He J.W., Milstein S.L., and Lai M.M. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38 (2003) 869-878
109. Zeuzem S. Heterogenous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?. Ann. Intern. Med. 140 (2004) 370-381
110. Zhang Y., Jamaluddin M., Wang S., Tian B., Garofalo R.P., Casola A., and Brasier A.R. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Virol. 77 (2003) 5933-5947
111. Zhou S., Lui R., Baroudy B.M., Malcolm B.A., and Reyes G.R. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310 (2003) 333-342